| 药品通用名/英文 |
NDC号/批准号 |
商标名 |
成份名 |
剂型 |
公司/生产厂 |
上市国/产地 |
规格/包装规格 |
备注 |
操作 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca AB
|
Sweden |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
MedImmune Pharma B.V./AstraZeneca AB
|
Nederland/Sweden |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
MedImmune Pharma B.V./AstraZeneca AB
|
Nederland/Sweden |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
HK-65928 |
Imfinzi |
durvalumab |
injection |
ASTRAZENECA HONG KONG LTD |
HONG KONG |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
HK-65929 |
Imfinzi |
durvalumab |
injection |
ASTRAZENECA HONG KONG LTD |
HONG KONG |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca/MedImmune UK Limited（MedImmune Pharma BV
） |
france/UK（Nederland） |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca/MedImmune UK Limited（MedImmune Pharma BV
） |
france/UK（Nederland） |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca GmbH/MedImmune UK Limited（MedImmune Pharma BV
）
|
Germany/UK（Nederland） |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca GmbH/MedImmune UK Limited（MedImmune Pharma BV
）
|
Germany/UK（Nederland） |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 瑞波西利片 |
0078-0860-01 |
KISQALI |
ribociclib |
tablet |
Novartis Pharmaceuticals Corporation |
USA |
200mg*21tablets/box |
|
请先登录 |
| 瑞波西利片 |
0078-0867-42 |
KISQALI |
ribociclib |
tablet |
Novartis Pharmaceuticals Corporation |
USA |
400mg*42tablets/box |
|
请先登录 |
| 瑞波西利片 |
0078-0874-63 |
KISQALI |
ribociclib |
tablet |
Novartis Pharmaceuticals Corporation |
USA |
600mg*63tablets/box |
|
请先登录 |
| 瑞波西利片 |
|
KISQALI |
ribociclib |
tablet |
Novartis Pharmaceuticals UK Ltd. /Novartis Pharma GmbH |
UK/Germany |
200mg*21，42,63,126,189tablets/box |
|
请先登录 |
| 瑞波西利片 |
|
KISQALI |
ribociclib |
tablet |
Novartis Pharmaceuticals UK Ltd. /Novartis Pharma GmbH |
UK/Germany |
400mg*21，42,63,126,189tablets/box |
|
请先登录 |
| 瑞波西利片 |
|
KISQALI |
ribociclib |
tablet |
Novartis Pharmaceuticals UK Ltd. /Novartis Pharma GmbH |
UK/Germany |
600mg*21，42,63,126,189tablets/box |
|
请先登录 |
| 瑞波西利片 |
|
KISQALI |
ribociclib |
tablet |
Novartis Pharma S.A.S./Novartis Pharma GmbH |
FRANCE/Germany |
200mg*21，42,63,126,189tablets/box |
|
请先登录 |
| 瑞波西利片 |
|
KISQALI |
ribociclib |
tablet |
Novartis Pharma S.A.S./Novartis Pharma GmbH |
FRANCE/Germany |
400mg*21，42,63,126,189tablets/box |
|
请先登录 |
| 瑞波西利片 |
|
KISQALI |
ribociclib |
tablet |
Novartis Pharma S.A.S./Novartis Pharma GmbH |
FRANCE/Germany |
600mg*21，42,63,126,189tablets/box |
|
请先登录 |
| 瑞波西利片 |
HK-65561 |
KISQALI |
ribociclib (as succinate) |
tablet |
NOVARTIS PHARMACEUTICALS (HK) LIMITED |
HONG KONG |
200 MG |
|
请先登录 |
| 司利弗明注射液 |
0078-0958-19 |
KYMRIAH |
tisagenlecleucel |
injection |
Novartis Pharmaceuticals Corporation |
USA |
10ML-50ML/BAG |
|
请先登录 |
| 司利弗明注射液 |
0078-0846-19 |
KYMRIAH |
tisagenlecleucel |
injection |
Novartis Pharmaceuticals Corporation |
USA |
10ML-50ML/BAG |
|
请先登录 |
| 司利弗明注射液 |
|
KYMRIAH |
tisagenlecleucel |
injection |
Novartis Pharmaceuticals UK Ltd. /Novartis Pharma GmbH |
UK/Germany |
(1.2 x 106
– 6 x 108)
10ML-50ML/BAG |
|
请先登录 |
| 司利弗明注射液 |
|
KYMRIAH |
tisagenlecleucel |
injection |
Novartis Pharma S.A.S./Novartis Pharma GmbH |
france/Germany |
50ml*3bag/box |
|
请先登录 |
| 司利弗明注射液 |
|
KYMRIAH |
tisagenlecleucel |
injection |
Novartis Pharma S.A.S./Novartis Pharma GmbH |
france/Germany |
250ml*3bag/box |
|
请先登录 |
| 司利弗明注射液 |
|
KYMRIAH |
tisagenlecleucel |
injection |
Novartis Pharma GmbH/Novartis Pharma GmbH |
Germany |
10ML-50ML/BAG |
|
请先登录 |
| 马来酸奈拉替尼片 |
70437-240-18 |
Nerlynx |
neratinib |
tablet |
Puma Biotechnology, Inc. |
USA |
40 mg*180 tablets/BOX |
|
请先登录 |
| 马来酸奈拉替尼片 |
70437-240-26 |
Nerlynx |
neratinib |
tablet |
Puma Biotechnology, Inc. |
USA |
40 mg*126 tablets/BOX |
|
请先登录 |
| 米哚妥林胶囊 |
0078-0698-99 |
Rydapt |
midostaurin |
capsule |
Novartis Pharmaceuticals Corporation |
USA |
25 mg*28cap/box |
|
请先登录 |
| 米哚妥林胶囊 |
0078-0698-19 |
Rydapt |
midostaurin |
capsule |
Novartis Pharmaceuticals Corporation |
USA |
25 mg*56cap/box |
|
请先登录 |
| 米哚妥林胶囊 |
|
Rydapt |
midostaurin |
capsule |
Novartis Pharmaceuticals Corporation |
france |
25mg*56cap，112cap/box |
|
请先登录 |
400-8577-888